Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

By João L. Carapinha

June 5, 2025

The Dutch Healthcare Institute (ZIN) has recommended trastuzumab deruxtecan (Enhertu) for inclusion in the Netherlands’ basic insurance package for HER2-low metastatic breast cancer. This recommendation is contingent on a price reduction exceeding 68%. The DESTINY-Breast04 trial demonstrated a median overall survival (OS) benefit of 6.6 months compared to chemotherapy. Despite this efficacy, the incremental cost-effectiveness ratio (ICER) of €219,803 per quality-adjusted life year (QALY) far exceeds the Dutch threshold of €80,000, necessitating significant price concessions. The ZIN emphasizes concerns over missing quality-of-life (QoL) data and variability in HER2-low diagnostic standardization, which could impact real-world effectiveness and cost calculations.

Clinical and Economic Insights

Efficacy and Diagnostic Challenges

Trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, has redefined treatment paradigms for HER2-low breast cancer, a subtype historically classified as HER2-negative. The DESTINY-Breast04 trial showed a 38% reduction in progression-free survival (PFS) risk (median PFS: 13.2 vs. 8.1 months) and a 36% OS improvement, establishing it as a first-line option post-endocrine therapy. However, HER2-low identification relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), with variability in testing methods leading to potential misclassification. The ZIN highlights the need for standardized diagnostics, aligning with the Ventana UltraView assay used in clinical trials, to ensure equitable patient access.

Cost-Effectiveness and Budget Impact

The ZIN’s cost-effectiveness analysis estimates a budget impact of €40.6 million annually by year three, treating approximately 475 patients. At current pricing, Enhertu’s lifetime treatment cost (€136,751) dwarfs chemotherapy (€41,902), driven by its €9,574 per-cycle list price. This aligns with broader European trends, where England’s NICE rejected Enhertu due to exceeding acceptable cost-effectiveness ranges. In Germany, similar debates have arisen, with the G-BA noting insufficient comparative data for HER2-mutated NSCLC.

Global Context and Policy Implications

Epidemiological and Health System Considerations

HER2-low breast cancer represents approximately 60% of HER2-negative cases, with higher prevalence in hormone receptor (HR)-positive tumors. The WHO’s Global Breast Cancer Initiative aims to reduce mortality by 2.5% annually, yet disparities persist. The five-year survival rate in high-income countries exceeds 90%, compared to only 40% in South Africa. Enhertu’s approval in the EU for HER2-low and HER2-ultralow tumors (April 2025) reflects shifting diagnostic thresholds, but affordability remains a barrier in lower-resource settings.

Enhertu Reimbursement Analysis and Pricing Dynamics

The ZIN’s demand for a more than 68% price reduction resonates with stringent European cost-containment strategies. In Germany, the G-BA evaluates therapies under §35a SGB V, often requiring comparative effectiveness data absent in single-arm trials. The Netherlands’ threshold of €80,000/QALY, adjusted for disease severity, contrasts with Germany’s implied threshold of approximately €90,000/QALY. These disparities highlight tensions between innovation incentives and fiscal sustainability, especially as developers explore label expansions into gastric and NSCLC indications.

Recommendations for Health Economics and Outcomes Research (HEOR)

  1. Real-World Evidence Generation: Post-marketing studies should address QoL gaps and long-term survival data absent from pivotal trials. Registries tracking HER2-low diagnostic consistency (e.g., IHC 1+ vs. 2+/ISH-) could optimize patient selection.
  2. Value-Based Pricing Models: Outcomes-based agreements, such as the Netherlands’ proposed two-year financial arrangement, could link reimbursement to real-world effectiveness while mitigating budget shocks.
  3. Diagnostic Harmonization: Collaboration between pathologists and payers, as seen in the Dutch HER2-low standardization initiative, is critical to ensuring equitable access and reducing geographic treatment disparities.

The Enhertu reimbursement analysis encapsulates the growing imperative for alignment between clinical innovation, health technology assessment (HTA) methodologies, and affordability safeguards in an era of precision oncology. As HER2-targeted therapies expand into earlier lines and novel subtypes, stakeholders must balance therapeutic promise with sustainable financing—a challenge epitomized by the Dutch ZIN’s cautious endorsement.

For a deeper background on these findings, refer to the original guidelines here.

Reference url

Recent Posts

pharmaceutical industry Europe
    

Pharmaceutical Industry Europe: Key Insights and Future Challenges for 2025

💡 How is the pharmaceutical industry in Europe poised to navigate the challenges of 2025?

As the industry faces fierce competition, regulatory hurdles, and evolving market dynamics, this article provides key insights into R&D investments, employment trends, and the urgent need for policy reforms. Discover how Europe can leverage its strengths to maintain its leadership in global life sciences.

Jump into these pivotal developments and strategies by reading the full article!

#SyenzaNews #pharmaceuticals #healthcarepolicy

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.